The Conversation (0)
Rafarma Pharmaceuticals Inc (PINKSHEETS:RAFA) announced that it has registered its 3rd-generation cephalosporin antibiotic, CEFTRIAXONE, as a drug under international unpatented label and will be used as treatment of bacterial meningitis, pneumonia, pediatric sepsis and gonorrhea.
Rafarma Pharmaceuticals Inc (PINKSHEETS:RAFA) announced that it has registered its 3rd-generation cephalosporin antibiotic, CEFTRIAXONE, as a drug under international unpatented label and will be used as treatment of bacterial meningitis, pneumonia, pediatric sepsis and gonorrhea.
As quoted in the press release:
Dave Anderson, CEO of Rafarma Pharmaceuticals, said, “Registering this product is complementary to our goal of producing high-quality pharmaceutical products. Rafarma is positioned to meet rising market demand for CEFTRIAXONE utilizing our state-of-the-art research facility and staff as we continue efforts to expand our product portfolio.
Click here to read the full Rafarma Pharmaceuticals Inc (PINKSHEETS:RAFA) press release.
